; (B) shall not be an entity that— (i) is involved in the manufacturing, research, and development of drugs; or (ii) operates fully insured or self-insured health plans, pharmaceutical benefit managers, or other entities that pay for drugs; and (C) shall be, as determined by the Secretary, independent of any other entity described in subparagraph (B). (3) Information (A) Information in possession of HHS The Secretary shall ensure that the entity under contract to develop an independent value assessment under this section has access to all of the information in the possession of the Department of Health and Human Services that is necessary to complete the assessment. (B) Information in possession of manufacturer The manufacturer of any drug for which an independent value assessment is being developed under this section shall, at the request of the Secretary or the entity under contract to develop the independent value assessment, provide to the Secretary or entity, as applicable, information in the possession of the manufacturer that is necessary to complete the assessment. (C) Patient input The Secretary shall ensure that any organization under contract to develop an independent value assessment under this section for a drug solicits from and takes into consideration the impact on patients who use the drug. (D) Additional information An entity under contract to develop an independent value assessment under this section for a drug shall offer manufacturers, patients, patient advocates, clinical experts, and members of the public an opportunity to submit additional information and analyses for consideration before the independent value assessment is complete. (e) Prohibitions The Secretary shall prohibit the use in any independent value assessment under this section of— (1) any analysis based on the quality-adjusted life year